TCB-002 is under clinical development by TC BioPharm and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TCB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TCB-002 (OmnImmune) is under development for the treatment of relapsed or refractory acute myeloid leukaemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL) and multiple myeloma, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), myeloproliferative neoplasms and ovarian cancer. The drug candidate consists allogeneic CD3+ T lymphocytes ex vivo expanded expressing the Vgamma9Vdelta2 T-cell (gamma delta T cells) receptor. It is administered through parenteral route. It is being developed based on CryoTC technology.
The drug candidate was also under development for Epstein Barr associated pneumonia.
TC BioPharm overview
TC BioPharm is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products. The company’s pipeline products are intended for the treatment of ovarian cancer, breast cancer and epidermolysisbullosa related disease, among others. It works in collaboration with various cancer centers in Glasgow, Edinburgh and Southampton to develop ImmuniCell, among others. The company provides clinical manufacturing facility which is located in Holytown, Scotland, the UK. TC BioPharm is headquartered in Glasgow, Scotland, United Kingdom.
For a complete picture of TCB-002’s drug-specific PTSR and LoA scores, buy the report here.